Revvity reported FY 2025 revenue of USD 2.9 billion, up 4.0%, including an approximate 1% benefit from foreign exchange. FY 2025 gross margin was 54.8% (down 104 basis points) and operating margin declined 10 basis points, reflecting tariff impacts, unfavorable foreign exchange and product mix shifts, partly offset by productivity and cost containment initiatives. Income from continuing operations in FY 2025 was USD 239.9 million, with an effective tax rate of 10.6%. By segment, FY 2025 Life Sciences revenue was USD 1.4 billion (up 2.0%), driven by a USD 35.6 million increase in Software revenue, while Diagnostics revenue was USD 1.4 billion (up 5.0%), led by Immunodiagnostics (up USD 41.3 million) and Reproductive Health (up USD 27.2 million). FY 2025 segment operating income was USD 458.3 million in Life Sciences and USD 344.2 million in Diagnostics, with margin pressure cited from foreign exchange, tariffs and product mix, including China diagnostic testing policy changes. Revvity said tariffs enacted and implemented during FY 2025 increased cost of revenue by approximately USD 25.0 million, with mitigation efforts reducing the net gross margin impact to approximately USD 20.0 million, primarily affecting products manufactured in Europe and sold in the U.S. The company also highlighted restructuring actions tied to workforce reductions and facility consolidations, affecting approximately 5% of its workforce, and said it expects to increase capital expenditures in FY 2026 to enhance digital capabilities, product innovation and realign production infrastructure. Cash and cash equivalents were USD 919.9 million at December 28, 2025, and the company had a new USD 1.5 billion revolving credit facility in place through January 7, 2030. In FY 2025, Revvity repurchased USD 820.8 million of shares and paid USD 32.8 million in dividends, and it expects to repay its EUR 500.0 million 1.875% senior unsecured notes due in 2026 using cash on hand, revolver borrowings, or a combination.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revvity Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000031791-26-000012), on February 24, 2026, and is solely responsible for the information contained therein.